Viatris (VTRS)

Executive Summary

Viatris is a global pharmaceutical company formed in 2020 through the merger of Mylan and Pfizer's Upjohn business. It boasts a diversified portfolio spanning branded, generic, complex generic, biosimilar, and OTC products across over 165 countries. The company's strategy centers on lifecycle management of its extensive portfolio, leveraging its global scale and supply chain to drive growth and profitability. With a pipeline of 247 drug candidates, Viatris is well-positioned to navigate patent cliffs and capture market opportunities in key therapeutic areas such as cardiology, immunology, and central nervous system disorders. The company's focus on debt reduction and margin improvement has been well-received by investors, and its strong cash flow supports both organic investment and bolt-on acquisitions. However, pricing pressures and competition from generics remain headwinds. Overall, Viatris represents a value-oriented investment with a clear path to sustainable earnings growth, driven by its diversified product base and upcoming catalysts.

Upcoming Catalysts (preview)

• 2026FDA decision on biosimilar for Stelara (ustekinumab)70% success
• 2026Launch of generic Entresto (sacubitril/valsartan) following bioequivalence study60% success
• 2026Strategic divestiture of non-core assets to further reduce debt80% success